News

Q3 FY25 Investor Briefing

7 May 2025

Lumos CEO and MD, Doug Ward, and CFO, Barrie Lambert, this week presented the Company's Q3 FY25 quarterly results. The presentation covers recent achievements including an update on the FebriDx CLIA Waiver study, strategic partnership agreements, and key priorities for the next quarter.

Take a look:

Related news

Quarterly Activity Statement & 4C | Period ending 31 March 2025

29 April 2025

Lumos secures additional US Medicare reimbursement coverage for FebriDx®

23 April 2025

Inquire now

We are inviting qualified B2B Service inquiries for those seeking to develop point-of-care reader technology

By entering your email address you are agreeing to our Privacy Policy.

Innovation at the point-of-care

2024 Lumos Diagnostics